Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sophonix of Beijing Closes $14 Million Round for Point-of-Care-Tests

publication date: Jun 24, 2020

Sophonix (Beijing Meilian Tyco Biotech) closed a $14 million Series B financing led by Zero2IPO Asset Management. The company is developing chemiluminescence point-of-care-tests (POCT) for pathological diagnosis and immunodiagnosis. Sophonix, which has R&D facilities in Beijing and California, has built a product portfolio of instruments and reagents with independent intellectual property rights. The B round included investments from Delian Capital, Anlong Capital, GoldTech Capital, Mingshi Investment and ETP. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China